Actelion launches new 20 mcg/mL Ventavis formulation

Sep 2 2009

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance. The 20 mcg/mL formulation of Ventavis(R) is available immediately for pre-order, and fulfillment of initial prescriptions by specialty pharmacies is anticipated beginning the week of September 14.

"Ventavis(R) is the leading inhaled prostacylin therapy for patients with PAH, and this stronger formulation is a major advancement. Together with the easy-to-use, compact inhalation device called the I-neb AAD System, it will offer even more convenience to patients using Ventavis," said Kirk Taylor, M.D., Senior Vice President, U.S. Medical Group at Actelion Pharmaceuticals US.

"Ventavis(R) is the inhaled prostacyclin with the most extensive clinical experience, and is an extremely important treatment option for many patients with PAH. Shortening treatment times by 50% with the new 20 mcg/mL concentration will significantly benefit my patients," said Dr. Richard Channick, Professor of Medicine, Pulmonary and Critical Care Division, UC San Diego Medical Center and Editor-in-Chief, Advances in Pulmonary Hypertension.

About Ventavis(R)

Ventavis(R) is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with NYHA Class III or IV symptoms. In August 2009, the U.S. Food and Drug Adminsitration approved the new 20 mcg/ml formulation of Ventavis(R).

Ventavis(R) is an inhaled synthetic analog of prostacyclin (PGI2) that produces potent pulmonary vasodilation and inhibits platelet aggregation, among other benefits. Prostacyclin functions as a hormone, binding to receptors on smooth muscle cells, thereby affecting their function. Prostacyclin has multiple physiological effects, including vasodilation, inhibition of platelet aggregation, antiproliferation, anti-inflammation, and enhanced cardiac contractility.

In January 2007, Actelion announced the successful completion of its cash tender offer for shares of CoTherix, Inc., thereby strengthening its PAH franchise by adding Ventavis(R) to its product offerings in the United States. Bayer Schering Pharma - the inventor of Ventavis(R) - markets the drug as the first inhaled prostacyclin in Europe and other countries outside the US.

Source: http://www.4ventavis.com